Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population

• DOI: 10.4103/tjo.tjo_72_19
• Publication Date: 2019-12-03T10:04:53Z
• Authors: FranciscoJose Rod...; HernanAndres Rios; MaríaCamila Aguilar; ShirleyMargarita ...; Nancy Gelvez; Greizy Lopez; MarthaL Tamayo
• Keywords: macular degeneration; Macular degeneration; hispanic americans; Angiogenesis inhibitors; 610; angiogenesis inhibitors; RE1-994; polymorphism; Ophthalmology; 03 medical and health sciences; 0302 clinical medicine; Original Article; Hispanic Americans; Polymorphism

Age-related macular degeneration (AMD) is the leading cause of visual impairment in patients over 55 years. Currently, most common therapies for neovascular AMD (nAMD) are intravitreal antiangiogenics. Studies suggest that genetic factors influence on antiangiogenics therapy outcomes. The purpose this work was to establish association between complement factor H (CFH) (Y402H), age-related maculopathy susceptibility 2 (ARMS2) (A69S), and high-temperature requirement A1 (HTRA1) (rs11200638) polymorphisms response treatment with ranibizumab nAMD.A cross-sectional study 61 eyes nAMD treated performed. Association from CFH, ARMS2, HTRA1 established.The mean age 76.6 (51-91) Only 37.7% had a functional 26.2% an anatomic response. TT polymorphism Y402H CFH gene associated increased likelihood treatment. Otherwise, there not statistically significant rs11200638 rs10490924 ARMS 2.This suggests antiangiogenic main genes ARMS2. However, it found differed according genotype, suggesting further investigations needed if CC TC genotype may need be monitored more closely disease recurrence than genotype.